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Although vulvar cancer is a rare disease, an increase in its incidence, 
particularly in younger women, has been reported.[1-3] This increase in 
younger women has been associated with the presence of oncogenic 
human papillomavirus (HPV).[4-6] There are two aetiological pathways 
to vulvar cancer: the first is related to vulvar non-neoplastic epithelial 
disorders such as lichen sclerosus in older women, while the second 
involves younger women and is associated with high-risk HPV.[5,7-9]
The rate of HPV infection among women in South Africa (SA) is 
high. Africa had the highest prevalence of HPV (22.1%) in a large 
meta-analysis of women with normal cytology. A single SA study 
included in this meta-analysis estimated the HPV prevalence in 
SA women with normal cytology to be 15.5%.[10] Cervical cancer 
incidence rates mirror HPV prevalence, and as vulvar cancer has 
been linked to HPV infection, it follows that the prevalence of vulvar 
cancer in young women may also be increased in the SA population.
International literature quotes the mean age of women with vulvar 
cancer to be between 64 and 70 years, but the perception in the 
authors’ clinical unit in Cape Town, SA, is that women treated at our 
hospital are much younger.[11-13]
Objective
To quantify the burden of disease at a tertiary referral hospital and to 
describe the population of women with vulvar cancer with regard to 
age, cancer stage, treatment modalities and outcome.
Methods
A retrospective, descriptive observational study was undertaken. 
Data were collected from the records of all women diagnosed with 
vulvar cancer presenting to the Gynaecological Oncology Unit 
at Tygerberg Hospital, Cape Town, between 1 January 2001 and 
31 December 2014. All histological types except melanoma were 
included. The patients were restaged using the 2009 International 
Federation of Gynecology and Obstetrics  (FIGO) staging system to 
allow comparison. Where surgical staging was not performed, the 
stage was assigned based on metastatic investigations, including 
cytological investigation of suspicious lymph nodes and imaging 
results.
As HPV testing was not available at our institution, histological 
results of vulvar biopsies and resected specimens were checked for 
cellular HPV changes, koilocytes and usual-type vulvar intraepithelial 
neoplasia (uVIN) as well as lichen sclerosus.
Treatment of early-stage vulvar cancer was mainly surgical, 
including vulvectomy or radical local excision of the vulvar tumour 
and inguinofemoral lymphadenectomy. For advanced disease (FIGO 
stages 3 and 4), or if the anal or urethral sphincters were involved 
with cancer, the patients were treated with neoadjuvant chemo-
therapy to shrink the lesion and make sphincter-sparing surgery 
possible, or with primary chemoradiotherapy, or with an ano-
vulvectomy. Adjuvant radiotherapy (without chemosensitisation 
in the first 8  years of the study) was given after surgery if 
histopathology confirmed inguinofemoral lymph node metastases 
or if the tumour-free surgical margins were <8 mm and further 
excision was not possible.
Time to recurrence was calculated from the last date of treatment 
to the date of recurrence. Data were censored at the patients’ last 
follow-up visit before 31 December 2015. Disease-specific survival 
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was calculated from the date of primary treatment to the date of 
death, when known, or the date when the patient was considered 
terminally ill and no further palliative treatment other than analgesia 
would be offered.
Statistical analysis
Statistical analysis was carried out using IBM SPSS Statistics for 
Windows, version 22.0 (IBM, USA). Means were compared using 
Student’s t-test, and significance was set at p<0.05. Survival analysis 
was performed using Kaplan-Meier estimates.
Ethics approval
Ethics approval was obtained from the Stellenbosch University 
Health Research Ethics Committee (ref. no. S13/03/047).
Results
Study population
One hundred and eighty-two women presented to Tygerberg 
Hospital with vulvar cancer between January 2001 and December 
2014. Two women were excluded from the study; one was found 
to have a recurrence of vulvar cancer, with her initial diagnosis in 
1992, and the other was referred to our unit postoperatively for 
adjuvant treatment and no details of her initial presentation or 
surgery were available.
The mean (standard deviation (SD)) age of the women at diagnosis 
of vulvar cancer was 52.5 (15.5) years (range 24 - 102). The patient 
characteristics are shown in Table 1.
HPV changes, koilocytes and/or uVIN were documented as 
present in the vulvar specimens from 82 women. Nine women had 
histologically diagnosed lichen sclerosus. The mean age of women 
with underlying HPV infection was 50.4 years, which was significantly 
younger than that of the women with lichen sclerosus (68.6 years) 
(p<0.001). Of the 82 women with histological changes compatible 
with HPV, 72 had Pap smear results available: 62.5% (45/72) had 
an abnormal Pap smear, 23/72 having high-grade intraepithelial 
neoplasia (HSIL) and 22/72 low-grade intraepithelial neoplasia (LSIL).
Presenting symptoms
The median duration of symptoms before diagnosis was 6 months, 
with a wide range from incidental diagnosis at gynaecological 
examination for an abnormal Pap smear (7 women) to a duration of 
10 years in 2 women with lichen sclerosus. Women most commonly 
complained of a lesion on the vulva (67.0%), followed by pain 
(41.5%) and itching (21.6%). Fifty percent of women were seen at 
the oncology clinic within 18 days of diagnosis. One woman waited 
2 years and presented only after traditional remedies had failed 
to improve her condition. Another woman was afraid to come to 
hospital and presented 3.5 years after diagnosis with stage 4 disease.
Cancer stage
The breakdown of patients by stage (FIGO 2009) and primary treat-
ment modality is shown in Table 2. Stage was assigned on the basis 
of clinical examination, imaging and cytology in cases where patients 
were not surgically staged. In patients who were surgically staged, the 
number and size of lymph node metastases were not included in the 
earlier histology reports and stages 3a and 3b could therefore not be 
distinguished. Ninety-six patients (53.3%) had advanced-stage cancer 
of FIGO stage 3 or higher.
Treatment modalities and outcome
One hundred and thirteen patients (62.7%) had surgery as a primary 
treatment, 46 (40.7%) of them receiving adjuvant radiotherapy after 
surgery. Of all the patients treated with primary surgery, 72 (63.7%) 
were free of disease at their last follow-up visit. Of the remaining 
41 patients, 27 died, 18 from vulvar cancer and 9 from other causes, 
6 had progressive disease at their last visit, and 8 had defaulted from 
further care.
Table 1. Patient characteristics
Characteristic Patients, n*
Age (yr), mean 
(SD, range)
180 52.5 (15.5, 24 - 102)
Parity, median (range) 174 3 (0 - 12)
Married, n (%) 139 87 (62.6)
BMI (kg/m2), mean (SD, 
range) 
87 25.4 (6.6, 13.4 - 49.3)
Smoking, n (%) 165 103 (62.4)
Medical conditions, n (%)
Hypertension 180 72 (40.0)
Diabetes 180 24 (13.3)
Asthma 180 17 (9.4)
HIV 169 40 (23.7)
Pap smear, n (%)
Normal 144 72 (50.0)
LSIL 144 35 (24.3)
HSIL 144 37 (25.7)
SD = standard deviation; BMI = body mass index; LSIL = low-grade intraepithelial 
neoplasia; HSIL = high-grade intraepithelial neoplasia.
*Certain variables had missing data.
Table 2. Primary treatment modalities
FIGO stage Patients, n (%)
Primary treatment, n
Surgery
Chemoradio-
therapy
Neoadjuvant 
chemotherapy Palliative care
Defaulted 
treatment
1a 10 (5.5) 10 0 0 0 0
1b 61 (33.9) 53 1 2 1 4
2 13 (7.2) 8 1 2 2 0
3a + 3b 41 (22.8) 29 2 2 3 5
3c 14 (7.8) 9 0 1 2 2
4ai 14 (7.8) 3 2 3 5 1
4aii 17 (9.4) 1 0 5 9 2
4b 10 (5.6) 0 1 0 8 1
Total 180 (100) 113 7 15 30 15*
FIGO = International Federation of Gynecology and Obstetrics.
*15 patients did not attend for primary treatment.
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Seven patients had primary chemoradiotherapy as treatment. They 
received external-beam radiotherapy of 45 Gy plus additional electron 
therapy to the vulva, with sensitisation with cisplatin or mitomycin C 
and 5-fluorouracil. Four of these patients were free of disease at follow-
up, 2 died of disease and 1 defaulted from further care.
Fifteen patients were treated with neoadjuvant chemotherapy 
(NACT), regimens including various combinations of vincristine, 
bleomycin, mitomycin C, cisplatin and 5-fluorouracil. One patient 
died of an arterial occlusion during her chemotherapy course. 
Surgery was carried out in 6 patients after NACT. Radiotherapy 
was given to 3 patients after NACT where surgery was not feasible. 
Palliative radiotherapy was given to 2 patients who had progressive 
disease after NACT. In total, 3 patients were free of disease at their 
last follow-up visit, 2 patients had progressive disease, 7 patients died 
and 3 defaulted from further treatment.
Surgical excision of the tumour usually involved vulvectomy in 
the first few years of the study and radical local excision thereafter. 
Lymphadenectomy included inguinal and femoral nodal dissection, 
but not dissection of the pelvic nodes. Unilateral lymphadenectomy 
was only performed in 3 patients with stage 1b disease. The surgical 
procedures performed and the number of recurrences in patients 
who had primary surgery are shown in Table 3.
Recurrence and survival
Forty-one patients had a recurrence of disease after treatment. 
The median time to recurrence was 308 (range 18 - 3 398) days. 
After treatment of the recurrence, 9 patients, who underwent 
surgical resection of the recurrent tumour, had a complete response, 
5  patients were living with disease, 26 patients died from vulvar 
cancer and 1 patient with disease died of pulmonary tuberculosis.
Overall, 54 of the 153 patients with known outcome (23 patients 
defaulted from care after their first oncology clinic visit or directly 
after primary treatment) died from vulvar cancer during the study 
period. The overall 5-year probability of survival for all stages was 
58.8%. The survival curves for each stage are shown in Fig. 1. Five-
year survival probabilities were 91.2% for stage 1, 82.5% for stage 2, 
41.0% for stage 3 and 10.9% for stage 4.
Discussion
The main finding of this retrospective study was that women referred 
to Tygerberg Hospital with vulvar cancer are on average 10 - 15 years 
younger than women with vulvar cancer in high-income countries. 
The mean (SD) age of women with at Tygerberg Hospital was 52.5 
(15.5) years. The median age in a Surveillance, Epidemiology and 
End Results (SEER) database study from the USA was 67 years 
(2003 - 2007), the median age from a nationwide database in The 
Netherlands was 70.4 years (1992 - 2005), and the average age 
in Australia was 64 years (1988 - 2009).[11-13] In a small study of 
37  patients in India the average age was 55.4 years, which is more 
comparable to our study.[14]
The reason for the age discrepancy between our study and studies 
in developed countries may be the high rate of HPV infection in the 
SA population. Women with HPV-related vulvar cancer are known 
to be younger than those with cancers originating from epithelial 
disorders such as lichen sclerosus.[8] In a comparison between HPV-
positive and HPV-negative vulvar cancers, Gargano et al.[4] found the 
median ages of women to be 61 and 75 years, respectively. Although 
formal testing for HPV in our study was not possible, histological 
findings compatible with underlying HPV were present in 82 women. 
These women were significantly younger (50.4 years) than those with 
lichen sclerosus (68.6 years) (p<0.001).
Fifty percent of women with vulvar cancer had an abnormal (LSIL 
or HSIL) Pap smear, which is an indication of the high prevalence 
of HPV infection in this population. The prevalence of HSIL in 
the general population in the Western Cape Province of SA is 4.2 - 
5.2%, according to National Health Laboratory Services statistics 
(G Neethling, personal communication 19 May 2017). Tobacco 
smoking, another risk factor for HPV acquisition, was reported by 
62.4% of women with vulvar cancer in our study, compared with 
26.8% of females in the Western Cape in a recent study.[15] HIV 
Table 3. Type of surgery
FIGO stage Patients, N
Patients with 
primary 
surgery, N
Type of surgery, n
Patients with recurrence 
of disease after surgery, 
n (%)
Nodal 
excision only
Excision 
of vulvar 
tumour
Tumour + 
nodal excision
Ano-
vulvectomy + 
nodes
1 71 63 19 44 14 (22.2)
2 13 8 1 4 3 0 (0)
3 55 38 3 28 7 15 (39.5)
4 41 4 3 1 2 (50.0)
Total 180 113 4 19 79 11 31/105* (29.5)
FIGO = International Federation of Gynecology and Obstetrics.
*8 patients defaulted from care after surgery.
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Fig. 1. Five-year disease-specific survival according to International Federa-
tion of Gynecology and Obstetrics (FIGO) stage.
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infection was diagnosed in 23.7% of women with vulvar cancer, 
which is also higher than the background prevalence of 7.8% of adults 
or 16.9% of antenatal patients in the Western Cape in 2012.[16,17] The 
link between HIV and HPV is well known and has been described in 
many studies on cervical cancer.
Although the median duration of patient-reported symptoms 
before diagnosis was only 6 months, 53.3% of women had advanced-
stage cancer of FIGO stage 3 or higher. The literature reports that 
approximately a third of women present with advanced-stage cancer, 
which was reported in 26.2% of 394 women from Queensland, 
Australia, 37.9% of 269 women from The Netherlands, and 32.4% 
of 8 101 women from the SEER registry.[11,13,18] As stage and lymph 
node status are the main prognostic predictors in vulvar cancer, 
further studies need to address the reasons for late presentation of our 
patients to our institution if we are to improve survival.[19]
Surgery was the most common treatment modality employed to 
treat women with vulvar cancer (n=113, 62.7%). For locoregional 
disease, vulvar surgery (radical local excision with adequate margins) 
and inguinofemoral lymphadenectomy, or a sentinel node procedure 
in appropriate patients, remains the treatment of choice for the 
best survival outcome.[20] A few patients were treated with primary 
radiotherapy (n=7) or NACT (n=15), with varying responses. A 
Cochrane review comparing treatment modalities in advanced-
stage cancer found no difference in survival between primary 
surgery, neoadjuvant chemoradiation and primary chemoradiation, 
but analyses were restricted to single studies in each comparison. [19] 
NACT has also been utilised in advanced-stage cancer, mainly 
to decrease tumour size in order to optimise complete surgical 
resection; however, the studies are all small and have not shown any 
evidence that survival is improved.[21] Most studies address survival 
outcomes in older women, but the optimal management of vulvar 
cancer in young women, particularly with respect to physical and 
sexual aspects of quality of life, still needs to be addressed.
Recurrence of disease after treatment occurred in 33.3% of women 
who were followed up. This is in keeping with other reported studies, 
where recurrence occurred in approximately one-third of patients.[22] 
Recurrence indicated a poor prognosis, as 26 of the 41 patients died. 
The 9 patients with complete response after recurrence all had the 
recurrent tumour removed surgically, 7 from the vulva and 2 from 
the groin. Groin recurrence has been associated with a 5-year survival 
rate of 0 - 8%.[23] Seventy-eight percent of recurrences occurred 
within the first 16 months after treatment. Patients should be closely 
followed up during this period so that cancer recurrence can be 
recognised timeously and early surgical treatment implemented 
where possible.
The survival statistics in this study are similar to those reported 
in the literature.[13] A large difference in survival probability between 
FIGO stage 2 (negative inguinofemoral lymph nodes) and stage 3 
(metastatic disease in lymph nodes) can be observed, showing that 
positive lymph nodes significantly worsen prognosis.[24,25]
Study strengths and limitations
Vulvar cancer is a rare disease, and accrual of a sizeable cohort of 
patients for a study is difficult. However, a significant number of 
patients with vulvar cancer are referred to, treated and followed up at 
our institution, a referral centre in a region of high HPV prevalence. 
Although the FIGO stage allocation changed twice over the time of 
this study, all the patients were restaged according to the latest (2009) 
staging system, and they were managed in the same cancer unit, 
where treatment protocols remained similar over the time period of 
the study, allowing for comparison and increasing the accuracy of 
survival analysis.
The study was limited by its retrospective design, including missing 
patient records and data, unavailability of laboratory results and loss 
of patients to follow-up. Although the complications of the various 
treatments were included in the data collection, the accuracy of these 
data was uncertain and further analyses were not performed. HPV 
testing was not available at the time of this study.
Because vulvar cancer is a rare disease, this cohort of patients 
will greatly add to the body of knowledge on the epidemiology and 
treatment of women with vulvar cancer.
Conclusions
In SA, vulvar cancer is not a disease of the elderly. Healthcare 
professionals should take cognisance of women’s symptoms, examine 
patients, and have a high index of suspicion of malignancy in vulvar 
lesions in younger women, especially those with abnormal Pap 
smears. It is essential that patients are diagnosed at an earlier stage if 
we are to reduce the morbidity of treatment and the mortality from 
vulvar cancer.
With the proven link of vulvar cancer to HPV, further research is 
necessary to determine the proportion of disease attributable to HPV 
in our setting, as well as to identify the strains of HPV involved. In 
the future, there may be a reduction in vulvar cancer as a result of 
introduction of the HPV vaccine. Surgical management of early-stage 
disease has a good prognosis, but the most appropriate and least 
morbid treatment for SA’s young population of women with advanced 
disease needs to be elucidated.
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